Search Results - therapeutics+%3e+oncology

140 Results

Sort By:

A Novel Chemical Modification of PROTACs (Proteolysis Targeting Chimeras) to Increase Selectivity in Hypoxic Environments (UCLA Case No. 2024-094)

UCLA researchers from the Department of Chemistry and Biochemistry have developed a novel chemical modification of PROTACs to increase their selectivity under hypoxic conditions. BACKGROUND: Proteolysis targeting chimeras (PROTACs) are molecules that induce targeted degradation of proteins by recruiting a ubiquitin ligase to a protein of interest...

Published: 3/18/2026 | Inventor(s): Stuart Conway

Keywords(s):

Category(s): Chemical > Synthesis, Therapeutics > Oncology

Targeted Protein Degradation in Cancer via Hypoxia-Activated PROTACs and Molecular Glues (UCLA Case No. 2024-095)

UCLA researchers from the Department of Molecular and Medical Pharmacology have developed a dual small-molecule platform for targeted protein degradation in cancer. By combining hypoxia-activated PROTACs with rationally designed molecular glues, this approach addresses key limitations in tumor selectivity. BACKGROUND: Despite major advances in cancer...

Published: 3/18/2026 | Inventor(s): Stuart Conway

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

UCHL1 Inhibitors, Modifications, and Uses Thereof (UCLA Case No. 2026-123)

UCLA researchers in the Department of Molecular & Medical Pharmacology and have developed novel, highly potent small-molecule inhibitors of UCHL1 that selectively suppress tumor growth and metastasis in aggressive cancers with favorable in vivo safety profiles. BACKGROUND: Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a dual-function enzyme...

Published: 3/11/2026 | Inventor(s): Tanya Stoyanova, Michael Jung

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Oncology > Oncology (Small Molecules)

Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)

UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...

Published: 3/4/2026 | Inventor(s): Lili Yang, Derek Lee, Tyler Halladay

Keywords(s):

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Hematology, Therapeutics > Autoimmune, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Infectious Diseases

Microbial Regulation of Immune Tolerance and Risk for Cancer (UCLA Case No. 2026-153)

Details available soon. Please contact UCLA Technology Development Group if you have any questions or would like more information in the meantime.

Published: 3/24/2026 | Inventor(s): Elaine Hsiao

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Partial Transcription Factor Reprogramming to Rejuvenate Exhausted Tumor-Specific T Cells into Stem-Like Memory T Cells (UCLA Case No. 2024-240)

UCLA researchers from the Department of Surgery have developed a novel approach to partially reprogram exhausted tumor-infiltrating T cells into stem-like memory T cells capable of durable tumor elimination. BACKGROUND: Adoptive cell therapies, such as tumor-infiltrating lymphocyte (TIL) therapy involve isolating T cells from a patient’s tumor,...

Published: 4/1/2026 | Inventor(s): Tyler McCaw, Joseph Crompton

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Stem Cells And Regenerative Medicine, Life Science Research Tools > Research Methods

Compositions and Methods to Modulate MAVS-Mediated Immunity (UCLA Case No. 2026-096)

UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics have developed methods to target TOM70, a mitochondrial outer membrane protein, to selectively modulate innate immune signaling and control pathological or protective immune responses across a range of clinical conditions. BACKGROUND: Innate immune detection of viral...

Published: 2/18/2026 | Inventor(s): Lena Pernas

Keywords(s):

Category(s): Diagnostic Markers > Targets And Assays, Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Platforms > Diagnostic Platform Technologies, Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Autoimmune, Therapeutics > Vaccines

The Use of Voltage Sensitive Mitochondrial Uncouplers as Selective Anti-Cancer Drugs (UCLA Case No. 2022-327)

UCLA researchers from the Department of Medicine have identified an anti-cancer drug that targets mitochondrial membrane potential to selectively kill tumor cells, showing efficacy for traditionally treatment-resistant lung cancers. BACKGROUND: Non-small cell lung cancer (NSCLC) is a devastating disease that will claim the lives of approximately 125,000...

Published: 2/17/2026 | Inventor(s): David Shackelford

Keywords(s):

Category(s): Therapeutics > Respiratory And Pulmonary, Therapeutics > Oncology

Regulated Gene Expression During Differentiation of Mature T Cells (UCLA Case No. 2022-147)

UCLA researchers from the Department of Pathology & Laboratory Medicine have developed a process to genetically modify stem cells to express transgenes in a regulated, stage-specific manner, avoiding the negative consequences of transgene expression during T cell development. Contact UCLA Technology Development Group for more information.

Published: 1/27/2026 | Inventor(s): Gay Crooks, Donald Kohn

Keywords(s):

Category(s): Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Inflammation And Inflammatory Diseases

Enhancing T Cell Production in Vitro From Stem and Progenitor Cells (UCLA Case No. 2022-257)

UCLA researchers from the Department of Pathology and Laboratory Medicine have developed an innovative differentiation method to increase T cell production for T cell immunotherapy. Contact UCLA Technology Development Group for more information.

Published: 1/27/2026 | Inventor(s): Gay Crooks, Christopher Seet

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

1 2 3 4 5 6 7 8 9 10 ...